Unified AMP PD Cohorts
Before clinical trials for new treatments can begin, researchers need thousands of volunteers building datasets and biosample banks, using the latest analysis methods and technologies.
Methods for Data Analysis
AMP® PD gives researchers access to a large, harmonized dataset with:
- common clinical and genomic data
- select clinical- and genetic- population information
plus proprietary, research-developed applications for visualizing and harmonizing data
News & Updates
Read latest news and updates related to AMP PD
- AMP PD in the news
- Advancements in research using AMP PD
- Grant and funding opportunities
- Program milestones and roadmap
Accelerating Medicine Partnership in Parkinson's Disease Webinar
AMP PD has officially launched and made available the first series of webinar training videos. These videos provide information on key concepts and live demonstrations, including:
- Signing up for access via the online portal
- Overview of the Google Cloud Platform (GCP)
- Interacting with AMP PD data via BigQuery
- Researcher Workbench (Terra) deep-dive
- Working with official AMP PD Workspaces
- NIH STRIDES Cloud overview
New Large-Scale Data Portal Will Promote Parkinson’s Treatment Development
The Accelerating Medicines Partnership (AMP) for Parkinson’s (PD) has opened a data portal with de-identified information from 4,298 Parkinson’s patients and healthy control subjects for use by scientists seeking new treatments for the progressive neurodegenerative disease.
Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease
The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease.
Massive NIH–industry project opens portals to target validation
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
Accelerating research for Parkinson's disease
Despite considerable ongoing translational and clinical research efforts, no disease-modifying drugs have been approved for Parkinson's disease. The Accelerating Medicines Partnership Parkinson's disease (AMP PD) programme, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease.
Collaborate with AMP PD
- Share data, methods, tools, and resources with the AMP PD community
- Apply for research grants